Message #11 From:
Stock News Bot Date: January 23, 2007 06:15:00 AM
CMPD News CompuMed, Inc. Announces Initiation of Coverage by Cohen Independent Research Group
LOS ANGELES--(BUSINESS WIRE)--CompuMed, Inc. (CMPD.OB), a medical informatics company leading the
development of advanced imaging technology for cost effective analysis
and monitoring, today announced that Cohen Independent Research Group, a
leading Wall Street research firm, has initiated coverage.
The report concludes, “CompuMed's unique
business model coupled with its aggressive expansion plans provides a
strong outlook for investors.”
"We are very pleased to have a leading research firm, such as Cohen
Independent Research, initiate coverage on CompuMed after an extensive
analysis of our business," said CEO, Jerry McLaughlin. "This thorough
report will provide the financial sector with valuable insight into our
opportunities, business strategy and the markets we have before us.”
About Cohen Independent Research Group:
Cohen Independent Research Group (CIRG) is a leading Wall Street
research firm. CIRG provides and distributes Wall Street
research-analyst coverage for a select group of companies with
outstanding business models. CIRG distributes in-depth stock market
research reports that highlight the company's market opportunity,
technology, management, competition and other key differentiators that
may affect their short and long term valuation. Visit CIRG at www.cohenresearch.com.
About CompuMed:
Founded in 1973, CompuMed, Inc. (CMPD.OB) is leading the development of
advanced imaging and medical informatics solutions that provide cost
effective analysis and monitoring. CompuMed focuses on cardiovascular
and musculoskeletal diseases, as well as other diseases associated with
aging populations. Its unique expertise in telemonitoring, imaging and
analysis facilitates the development of new solutions and services
designed to improve healthcare provider workflow and patient care, while
reducing costs. CompuMed's core products, the OsteoGram®
and CardioGram(TM) systems, are cleared by the FDA and reimbursable by
Medicare. The OsteoGram is an accurate and precise technology for
osteoporosis testing. The underlying OsteoGram technology has
significant cost advantages over other technologies and will be applied
to a suite of value-added applications, such as following the
progression of arthritic disease and diagnosing vertebral fractures and
scoliosis. The CardioGram system is one of the first telecommunication
networks designed to remotely interpret electrocardiograms, and is used
by private practice, as well as government and corporate healthcare
providers nationwide. The CardioGram delivers online electrocardiogram
interpretations within two minutes of receipt, and has the additional
capability to automatically provide an over-read (i.e., follow-up
review) by a cardiologist. CompuMed is headquartered in Los Angeles.
Visit CompuMed at www.compumed.net.
This news release contains forward-looking statements.
Forward-looking statements include statements concerning the Company's
plans, objectives, goals, strategies, future events or performance and
underlying assumptions and other statements that are not statements of
historical fact. These statements are subject to uncertainties and risks
including, but not limited to, product and service demand and
acceptance, changes in technology, ability to raise capital, the
availability of appropriate acquisition candidates and/or business
partnerships, economic conditions, the impact of competition and
pricing, capacity and supply constraints or difficulties, government
regulation and other risks identified in the Company's filings with the
Securities and Exchange Commission available at www.sec.gov.
All such forward-looking statements are expressly qualified by these
cautionary statements. In addition, the Company disclaims any obligation
to update any forward-looking statements to reflect events or
circumstances after the date hereof, except as required by law.
